Immunovant, Inc. 4

Immunovant CTO Jay S. Stout sold 3,487 shares of common stock on July 8, 2026, in non-discretionary “sell to cover” transactions related to RSU vesting.

On July 8, 2026, Immunovant, Inc. Chief Technology Officer Jay S. Stout sold an aggregate 3,487 shares of Immunovant common stock in four small, issuer-mandated “sell to cover” transactions tied to the vesting of previously granted restricted stock units from April 2024 and April 2025 awards. The sales, executed at weighted average prices of approximately $39.53 and $39.99 per share, were solely to satisfy tax withholding obligations upon RSU vesting and are explicitly characterized as non-discretionary under the company’s policy. Following these withholding-related sales, Stout continued to hold 208,198 shares of Immunovant common stock, implying a post-transaction equity stake worth roughly $8.3 million at the sale prices, indicating that his overall economic exposure to the company remains substantial.

Filing Facts

CIK

1764013

Ticker

IMVT

Form

4

Source Type

fda

Accession

0001764013-26-000081

Alert Tier

5